We support psychedelic #clinicaltrials with the methodological rigor and familiarity with the evolving regulatory landscape necessary to gain approvals. Explore our solutions and experience:➡️ https://hubs.li/Q02HM-2c0
Signant Health
Fabricația de produse farmaceutice
Blue Bell, Pennsylvania 110.689 adepți
The Evidence Generation Company
Despre noi
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.
- Site web
-
http://www.signanthealth.com
Link extern pentru Signant Health
- Sector de activitate
- Fabricația de produse farmaceutice
- Dimensiunea companiei
- 1.001 - 5.000 de angajați
- Sediu
- Blue Bell, Pennsylvania
- Tip
- Companie privată
- Specializări
- clinical trial software, eCOA, eConsent, IRT, Clinical Supply Optimization, Patient Engagement, Rater Training, Data Quality, Analytics, Scientific Consulting și Clinical Consulting
Locații
Angajați la Signant Health
-
John Hughes
Business Development and Operations Executive - enabling revenue growth through strategy, process, technology and culture.
-
Markku Lukkarinen
Senior UX Designer at Weasel Software
-
Joanne Kondan
Finance and Operations Leader, Specializing in Operational Effectiveness
-
Konstantin Kondakov
SRE / CloudOps / DevOps / TechOps / WebOps "hands-on"senior manager
Actualizări
-
Explore how computerized cognitive assessments in #oncologytrials revolutionize understanding Cancer-Related Cognitive Impairment (CRCI), transform trial protocols, and inform targeted interventions in our latest blog post by Viani Figueroa, PhD: https://hubs.li/Q02HtCfc0
-
-
Attention CROs! In our upcoming webinar, discover how a unified #eClinical platform gives you a competitive edge, enhances your offerings to sponsors, and streamlines site operations. Save your spot: https://hubs.li/Q02H4_XT0
-
-
Despite the potential benefits to patients, providers, and pharmaceutical companies, the absence of labeling related to Patient-Reported Outcome Measures has been striking. In this article in DIA's Global Forum, Anthony Todd Everhart, MD examines the challenges with PROMs in #cancertrials and proposes collaborative ways to overcome them: https://hubs.li/Q02GYbrR0
-
-
Look for us at #AAIC24 where we're discussing the role of cognitive assessments in #AlzheimersResearch and sharing interesting findings in these posters: 🌍 Geo-cultural Variation in MMSE Score Changes in Alzheimer's Trials 📊 MMSE and CDR Score Changes in Multinational Alzheimer's Trials 📑 Impact of Rater Change on MMSE Data: A Post-Hoc Analysis 📉 Impact of Site Size on Data Quality in Early Alzheimer's Disease Clinical Trials Meet our experts and get resources: https://hubs.li/Q02GLX_S0
-
Signant is pleased to announce the appointment of industry veteran Paul Richmond to chief commercial officer. Read how Paul will help guide our biotech, pharma, and CRO customers with selecting the right #eClinical solutions for their trials: https://hubs.li/Q02Gy7h80
-
-
In this perspective paper, Signant's Bill Byrom and industry colleagues explore opportunities, challenges, and strategies for leveraging sensor-based functional outcomes (SFBO) in #clinicaltrials. Explore their strategies and insights for optimizing evidence generation using SFBOs alongside other COAs: https://hubs.li/Q02G0nkP0 #digitalhealth
-
In our latest blog, Maria Visser and Martina Micaletto discuss the subjectivity of instruments used to measure #atopicdermatitis severity, the importance of data accuracy, and how different assessment methods can impact trial outcomes. Read more: https://lnkd.in/e4Y2VJKw #ClinicalTrials #DermatologyResearch
A closer look at key assessment methods and their impact on outcomes
https://www.signanthealth.com
-
Discover a simpler #clinicaltrial experience without compromising quality or functionality with Signant SmartSignals® Unified Platform. Say goodbye to managing multiple systems and vendors for each trial. Learn more: https://hubs.li/Q02Ffn7m0
See what sponsors and CROs have been asking for
https://www.signanthealth.com
-
In this podcast, Signant's Bill Byrom PhD, speaks with Julian Minett, CEO of Spencer Group, about the use of #AI and #MachineLearning in clinical #drugdevelopment. While covering a breadth of topics and application areas, one promising area they examine is how AI can be a useful tool in COA development and implementation, using case study illustrations. Listen now: https://hubs.li/Q02F3kVd0
The Future of eCOA & AI with Signant Health’s Bill Byrom - Spencer Group
https://spencergroup.com